Paris, July 22, 2021 – Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase
Paris, July 1st, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases,
Towards a new standard for device indication: Implantation for temporary or permanent use • Easy removal with a beating heart
by Jean-Alexandre Kaminisky, 2021-03-18 Karista invests in MyPL increasing its financing to €1.8m & accelerating its development Paris – France, March
by Jean-Alexandre Kaminisky, 2021-03-16 MyPL wins €1.1 Million European Union grant as part of Horizon Europe 2020 GerOnTe[1] project out of a
A major step and a critical milestone achieved prior to First In Human clinical trials FineHeart’s TET is a system
Paris, July 22, 2021 – Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase
Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study
Paris, July 1st, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases,
Towards a new standard for device indication: Implantation for temporary or permanent use • Easy removal with a beating heart
Latest Insights
French biotech company will use its bioSens-All proprietary technology to correlate impact of GPCR mutations on signaling pathways Results may
Paris, July 1st, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases,
Paris, January 7th, 2020 – PKvitality, a French company specialized in bio wearables, has signed an agreement with Beurer GmBH,
Paris, October 16, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including
Paris, November 23, 2020 – PKvitality, a French company specialized in bio wearables, has been rewarded by being named the